首页 | 本学科首页   官方微博 | 高级检索  
     


Nerve-sparing robotic radical hysterectomy: our technique
Authors:Shailesh P. Puntambekar  Akhil Lawande  Riddhi Desai  Rahul Kenawadekar  Saurabh Joshi  Geetanjali Agarwal Joshi
Affiliation:1. Galaxy CARE Laparoscopy Institute, Pune, Maharashtra, India
Abstract:Robotic surgery is now becoming accepted for treatment of gynaecological malignancies. Nerve preservation during radical hysterectomy is increasingly being offered due to improved post-operative bladder and sexual function. We aimed to demonstrate the feasibility of performing a nerve-sparing radical hysterectomy robotically and to assess the oncological and functional outcomes associated with this surgery. Between August 2011 and January 2013, a total of 12 non-consecutive patients underwent robotic surgery for early stage cervical cancer at our institution. Patients comprising FIGO stage IA2 to IB1 were treated with nerve-sparing robotic radical hysterectomy using a C1 (Querleu–Morrow classification) type technique. The feasibility, operative time, blood loss, oncological outcome and post-operative bladder function were assessed. All the procedures were completed robotically without conversion to laparoscopy or laparotomy. The mean age of the patients was 56 years (range 44–76) and their mean body mass index was 22.6 kg/m2 (range 18.1–26.4). The mean operative time was 156 min (range 120–250); the mean blood loss was 120 ml (50–250). The Foley catheter was removed on the third post-operative day, with full recovery of bladder function in all patients except one who required prolonged catheterisation for 3 weeks. Residual urine was 40 ml (range 30–80). Parametrial margins of 2.5–3 cm, distal vaginal margins of 2–2.5 cm and a mean nodal harvest of 24 (range 18–30) were achieved. The mean hospital stay was 3 days (range 2–6). The median follow-up is 12 months. There is no loco-regional recurrence. All the patients are sexually active. Robotic nerve-sparing radical hysterectomy is technically feasible to perform, and is oncologically safe for early stage cervical carcinoma.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号